Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: Reduced toxicity vs reduced intensity

A. Shimoni*, N. Shem-Tov, Y. Volchek, I. Danylesko, R. Yerushalmi, A. Nagler

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

47 Scopus citations

Fingerprint

Dive into the research topics of 'Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: Reduced toxicity vs reduced intensity'. Together they form a unique fingerprint.

Medicine & Life Sciences